Clinical Trials Browser

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

Clinical Trials

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

Neoadjuvant Tebentafusp for Uveal Melanoma

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

Tebentafusp-tebn With LDT in Metastatic UM

SALOME

SILVER

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

Adjuvant Quisinostat in High-Risk Uveal Melanoma

IHOPE

AMUM

PROQEM

Retrospective Register for Uveal Melanoma

A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma

UM